胃癌患者应用紫杉醇类药物的疗效与β-微管蛋白-Ⅲ表达的相关性  

Correlation between chemotherapeutic efficacy of paclitaxel and classⅢ β-tubulin protein expression in gastric carcinoma patients

作　　者：杨全良[1] 曾冬香[1] 刘永萍[1] 凌扬[1] 蒋华蔚[1] 马剑[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,213001

出　　处：《肿瘤研究与临床》2013年第2期94-95,99,共3页Cancer Research and Clinic

摘　　要：目的观察肿瘤组织β-微管蛋白-Ⅲ表达与晚期胃癌患者采用含紫杉醇方案化疗疗效的相关性。方法应用免疫组织化学检测晚期胃癌肿瘤组织中β-微管蛋白．Ⅲ表达。依据β-微管蛋白-Ⅲ表达情况分为低表达组（30例）和高表达组（30例）。入选者均行紫杉醇联合替吉奥方案化疗，每2个周期评价1次疗效。随访并记录总生存期及肿瘤进展时间。结果低表达组与高表达组患者客观反应率（RR）分别为53．3％（16／30）、36．7％（11／30）；总生存期（OS）分别为364、345d；肿瘤进展时间（TTP）分别为198、146d；低表达组RR率及TTP均优于高表达组，差异有统计学意义（P〈0．05）；两组OS差异无统计学意义（P〉0．05）。结论β-微管蛋白-Ⅲ可作为晚期胃癌含紫杉醇方案化疗疗效的预测指标；β-微管蛋白-Ⅲ低表达的胃癌患者，可能是含紫杉醇化疗方案的优势人群。Objective To investigate the predictive value of class Ⅲ β-tubulin protein expression in tumor tissue for the efficacy of taxol combined chemotherapy in stageⅢ_B/Ⅳ gastric carcinoma patients. Methods Tumor biopsy samples were obtained and class Ⅲ β-tubulin protein expression were examined by immunohistochemical staining before chemotherapy. According to different expression of class Ⅲ β-tubulin, the patients were divided into two groups, group A （low expression of classⅢ β-tubulin）, group B （high expression of class Ⅲ β-tubulin）. The patients were assigned to be received 4 to 6 cycles of Taxol and S-1 chemotherapy regimens and followed up until death or lost. Response rate （RR）, overall survival （OS） and time to tumor progression （TFP） were assessed. Results There was no significant difference in clinical characteristics among patients with different expression rate. The RR was higher and TIP was longer in group A than in group B （53.3 % vs 36.7 %, 198 days vs 146 days, P 〈 0.05 respectively）, and no significant differences of OS in two groups （P 〉 0.05）. Conclusion The expression level of class Ⅲ β-tubulin in tumor tissue is probably a predictor for the efficacy of taxol in gastric cancer patients, taxol combined chemotherapy is more suitable for patients with lower expression of class Ⅲ β-tubulin.

关 键 词：胃肿瘤 β-微管蛋白-Ⅲ 紫杉醇类药物 

分 类 号：R735.2[医药卫生—肿瘤]